""
Finance

10 Best Stocks Under $10

I have been writing investment commentary for over 20 years. And what I have come to clearly understand is that few things give investors more joy than buying stocks under $10.

Its like rummaging through the racks at TJ Maxx where 98% of the stuff is ugly and worthless. But ever now and then you come across that hidden gem. A low priced stock that explodes higher in price once other investors wake up to the fundamental virtue of the company.

The theory is great…the reality is a bit tougher to accomplish.

Meaning that most of these stocks at one time traded for more than $10. And what brought them down this lowly state is typically a string of bad earnings reports that had investors running away in droves.

So what makes a stock like Antares Pharma (ATRS) stand out?

The answer to that is a bit more evident when I share with you the main criteria used to unearth these top 10 stocks under $10.

  • 1,928 with POWR Rating of A or B. You know that these are the timeliest stocks given all 4 hurdles they had to clear to qualify in this proprietary quantitative model. (Learn more about what’s inside the POWR Ratings here).
  • 159 stocks remained that had a price of less than $10.
  • 67 stocks that recently had an earnings beat. This was the main criteria applied to help insure that fundamentals were headed in the right direction. Note that 60% of the stocks on this list actually failed this vital test.
  • 10 Stocks with the greatest upside from current price to average targets set on them by Wall Street analysts. Please remember that most target prices are only 10-20% above current levels. The only reason for an analyst to place such an extraordinarily high target on a stock is to feel that confident that is an accurate depiction of what it is truly worth.
See also  3 Renewable Energy Stocks to Invest in for a Biden White House

At the end of the day we are looking at 10 stocks with a healthy blend of positive fundamentals + momentum + low price + extreme value. Check them out below.

Company Ticker Market Cap ($mil) EPS Surprise % Price Target Upside %
Anavex Life Sci AVXL $179 7.14 $3.40 $12.00 252.94%
Bioxcel Thera BTAI $153 4.17 $9.72 $25.00 157.20%
Adma Biologics ADMA $301 3.12 $5.08 $10.25 101.77%
Compugen Ltd CGEN $219 17.65 $4.27 $8.50 99.06%
Pfenex Inc PFNX $271 52.00 $8.59 $17.00 97.90%
Affimed N.V. AFMD $215 118.75 $3.44 $6.67 93.90%
Durect Corp DRRX $420 20.00 $2.19 $3.96 80.82%
Antares Pharma ATRS $584 25.00 $3.58 $5.99 67.32%
Biodelivery Sci BDSI $414 37.50 $4.62 $7.42 60.61%
Quest Res Hldg QRHC $40 66.67 $2.58 $3.75 45.35%

What to Do Next?

I would recommend clicking on the links for the stocks that have the most appeal to you. That will take you to their respective quote pages on StockNews.com where you can find a more in-depth understanding of the stock.

I am referring to the full display of the POWR Ratings for the stock where we break it down into  4 components to appreciate the full attractiveness of the investment. a stock. That includes its Buy & Hold Grade, Trading Grade, Industry Rank and Peer Grade. Just click the ticker for each stock to discover that information and more.

One last thing…

Every day I share a limited number of top stocks through articles just like this one. However, you are cutting yourself short from all the resources of the POWR Ratings system that will help you find the best stocks to buy at any time. Not just speculative stocks like these, but large caps, high dividend, value, growth and momentum stocks.

See also  NVIDIA And AMD- Star Performers in The Technology Sector

Ratings are updated every day. And that includes updates on the stocks to sell before they harm your portfolio.

But they are only available to POWR Ratings Premium members. Gladly we have a 30 day free trial which is the best way to get started. Just click the link below to learn more and get started.

30 Day Free Trial to POWR Ratings Premium

 


ATRS shares were unchanged in after-hours trading Wednesday. Year-to-date, ATRS has gained 32.35%, versus a 20.75% rise in the benchmark S&P 500 index during the same period.

 

About the Author: Steve Reitmeister

Steve is better known to the StockNews audience as “Reity”. Not only is he the CEO of the firm, but he also shares his 40 years of investment experience in the Reitmeister Total Return portfolio. Learn more about Reity’s background, along with links to his most recent articles and stock picks. More…

More Resources for the Stocks in this Article

View more information: https://stocknews.com/news/atrs-10-best-stocks-under-10/

See more articles in category: Finance

Leave a Reply

Back to top button